**[INSERT INSTITUTION] Announces First Patient Treated with Tryton Side Branch Stent**

*Interventional cardiologists at [INSERT INSTITUTION] using new technology engineered for challenging anatomy of coronary bifurcation lesions involving large side branches.*

**[INSERT CITY, STATE] – [INSERT DATE] –** [INSERT INSTITUTION], [INSERT BRIEF DESCRIPTION OF INSTITUTION], today announced the completion of its first case using the Tryton Side Branch Stent to treat a coronary bifurcation lesion involving a large side branch (appropriate for a ≥2.5mm stent). The procedure was performed by [INSERT PHYSICIAN].

Coronary artery disease, the leading cause of death in the U.S. in both men and women, often results in the buildup of plaque at a site where one artery branches from another, also known as a bifurcation. Approximately 20-30% of all patients undergoing percutaneous coronary interventions to open blocked arteries have a bifurcation lesion. Provisional stenting of the main branch is the current standard of care, but in many cases the side branch is not stented, leaving it vulnerable to complications like occlusion requiring bailout stenting.

“[INSERT PHYSICIAN QUOTE],” said [INSERT PHYSICIAN].

The Tryton Side Branch Stent is a cobalt chromium stent based on Tri-ZONE® technology engineered to provide complete lesion coverage and more predictable patient outcomes. It is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel.

In February 2017, the Tryton Side Branch Stent became the first dedicated bifurcation stent to receive regulatory approval in the U.S. It is manufactured by Tryton Medical and distributed by Cordis. For more information, visit <https://www.cordis.com/en_us/cmp/ext/tryton-side-branch-stent.html>.

**About [INSERT INSTITUTION]**

[INSERT INSTITUTION BOILERPLATE]

**Contact**

[INSERT INSTITUTION MEDIA CONTACT]